Genetics of biliary tract cancers and emerging targeted therapies

Journal of Clinical Oncology

Volumn 28, Issue 21, 2010, Pages 3531-3540

  Hezel, Aram F ^a   Deshpande, Vikram ^a   Zhu, Andrew X ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; ANTINEOPLASTIC AGENT; ARRY 438162; BETA CATENIN; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; K RAS PROTEIN; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE; NEU DIFFERENTIATION FACTOR; OXALIPLATIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOINOSITIDE 3 KINASE ALPHA; SELUMETINIB; SMAD4 PROTEIN; SORAFENIB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; PIK3CA PROTEIN, HUMAN; RAS PROTEIN;

ADD ON THERAPY; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; BILE DUCT CARCINOMA; BILIARY INTRADUCTAL PAPILLARY NEOPLASM; BILIARY TRACT CANCER; CANCER GENETICS; CLINICAL DECISION MAKING; DRUG EFFICACY; DRUG SAFETY; FLUORESCENCE IN SITU HYBRIDIZATION; GALLBLADDER ADENOMA; GALLBLADDER CARCINOMA; GALLBLADDER MALFORMATION; GALLBLADDER TUMOR; GAP LIGASE CHAIN REACTION; GENE MUTATION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC ASSOCIATION; GENETIC SCREENING; GENOTYPE; HISTOPATHOLOGY; HUMAN; HYPERTENSION; IMMUNOHISTOCHEMISTRY; MOLECULAR GENETICS; MOLECULAR PATHOLOGY; NEUTROPENIA; NONHUMAN; ONCOGENE; ONCOGENE K RAS; OVERALL SURVIVAL; PATHOGENESIS; PERIPHERAL NEUROPATHY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVIEW; SIDE EFFECT; SINGLE STRAND CONFORMATION POLYMORPHISM; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE; ANIMAL; BILIARY TRACT TUMOR; DISEASE MODEL; GENETICS; PHYSIOLOGY; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; BILIARY TRACT NEOPLASMS; DISEASE MODELS, ANIMAL; GENES, TUMOR SUPPRESSOR; HUMANS; MAP KINASE SIGNALING SYSTEM; PROTO-ONCOGENE PROTEINS; RAS PROTEINS;

EID: 77955285782     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.27.4787     Document Type: Review

References (116)

1. Shaib Y, El-Serag HB: The epidemiology of cholangiocarcinoma. Semin Liver Dis 24:115-125, 2004 (Pubitemid 38738341)
2. Lee CH, Chang CJ, Lin YJ, et al: Viral hepatitis-associated intrahepatic cholangiocarcinoma shares common disease processes with hepatocellular carcinoma. Br J Cancer 100:1765-1770, 2009
3. El-Serag HB, Engels EA, Landgren O, et al: Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans. Hepatology 49:116-123, 2009
4. Eckel F, Schmid RM: Chemotherapy in advanced biliary tract carcinoma: A pooled analysis of clinical trials. Br J Cancer 96:896-902, 2007 (Pubitemid 46452283)
5. Jarnagin WR, Ruo L, Little SA, et al: Patterns of initial disease recurrence after resection of gall-bladder carcinoma and hilar cholangiocarcinoma: Implications for adjuvant therapeutic strategies. Cancer 98:1689-1700, 2003 (Pubitemid 37238626)
6. Mosconi S, Beretta GD, Labianca R, et al: Cholangiocarcinoma. Crit Rev Oncol Hematol 69:259-270, 2009
7. Wistuba II, Gazdar AF: Gallbladder cancer: Lessons from a rare tumour. Nat Rev Cancer 4:695-706, 2004 (Pubitemid 39215068)
8. Khan SA, Thomas HC, Davidson BR, et al: Cholangiocarcinoma. Lancet 366:1303-1314, 2005 (Pubitemid 41416587)
9. Thomas MB: Biological characteristics of cancers in the gallbladder and biliary tract and targeted therapy. Crit Rev Oncol Hematol 61:44-51, 2007
10. Olnes MJ, Erlich R: A review and update on cholangiocarcinoma. Oncology 66:167-179, 2004 (Pubitemid 38813042)
11. Anderson CD, Pinson CW, Berlin J, et al: Diagnosis and treatment of cholangiocarcinoma. Oncologist 9:43-57, 2004 (Pubitemid 38134013)
12. Hezel AF, Zhu AX: Systemic therapy for biliary tract cancers. Oncologist 13:415-423, 2008 (Pubitemid 351679921)
13. Maitra A, Hruban RH: Pancreatic cancer. Annu Rev Pathol 3:157-188, 2008 (Pubitemid 351488279)
14. Vogelstein B, Fearon ER, Hamilton SR, et al: Genetic alterations during colorectal-tumor development. N Engl J Med 319:525-532, 1988
15. Zen Y, Adsay NV, Bardadin K, et al: Biliary intraepithelial neoplasia: An international interobserver agreement study and proposal for diagnostic criteria. Mod Pathol 20:701-709, 2007 (Pubitemid 46788877)
16. Zen Y, Sasaki M, Fujii T, et al: Different expression patterns of mucin core proteins and cytokeratins during intrahepatic cholangiocarcinogenesis from biliary intraepithelial neoplasia and intraductal papillary neoplasm of the bile duct: An immunohistochemical study of 110 cases of hepatolithiasis. J Hepatol 44:350-358, 2006 (Pubitemid 43069217)
17. Abraham SC, Lee JH, Hruban RH, et al: Molecular and immunohistochemical analysis of intraductal papillary neoplasms of the biliary tract. Hum Pathol 34:902-910, 2003 (Pubitemid 37169620)
18. Klöppel G, Kosmahl M: Is the intraductal papillary mucinous neoplasia of the biliary tract a counterpart of pancreatic papillary mucinous neoplasm? J Hepatol 44:249-250, 2006
19. Zen Y, Fujii T, Itatsu K, et al: Biliary papillary tumors share pathological features with intraductal papillary mucinous neoplasm of the pancreas. Hepatology 44:1333-1343, 2006 (Pubitemid 44748384)
20. Nakanishi Y, Zen Y, Kondo S, et al: Expression of cell cycle-related molecules in biliary premalignant lesions: Biliary intraepithelial neoplasia and biliary intraductal papillary neoplasm. Hum Pathol 39:1153-1161, 2008
21. Hoang MP, Murakata LA, Katabi N, et al: Invasive papillary carcinomas of the extrahepatic bile ducts: A clinicopathologic and immunohistochemical study of 13 cases. Mod Pathol 15:1251-1258, 2002 (Pubitemid 35462991)
22. Yamagiwa H: Mucosal dysplasia of gallbladder: Isolated and adjacent lesions to carcinoma. Jpn J Cancer Res 80:238-243, 1989
23. Roa JC, Anabalón L, Roa I, et al: Promoter methylation profile in gallbladder cancer. J Gastroenterol 41:269-275, 2006
24. Duarte I, Llanos O, Domke H, et al: Metaplasia and precursor lesions of gallbladder carcinoma: Frequency, distribution, and probability of detection in routine histologic samples. Cancer 72:1878-1884, 1993
25. Albores-Saavedra J, Alcántra-Vazquez A, Cruz-Ortiz H, et al: The precursor lesions of invasive gallbladder carcinoma: Hyperplasia, atypical hyperplasia and carcinoma in situ. Cancer 45:919-927, 1980 (Pubitemid 10129841)
26. Roa I, de Aretxabala X, Araya JC, et al: Preneoplastic lesions in gallbladder cancer. J Surg Oncol 93:615-623, 2006 (Pubitemid 43855690)
27. Hanada K, Tsuchida A, Iwao T, et al: Gene mutations of K-ras in gallbladder mucosae and gall-bladder carcinoma with an anomalous junction of the pancreaticobiliary duct. Am J Gastroenterol 94:1638-1642, 1999 (Pubitemid 29260458)
28. Yanagisawa N, Mikami T, Saegusa M, et al: More frequent beta-catenin exon 3 mutations in gallbladder adenomas than in carcinomas indicate different lineages. Cancer Res 61:19-22, 2001 (Pubitemid 32095691)
29. Rashid A, Gao YT, Bhakta S, et al: Beta-catenin mutations in biliary tract cancers: A population-based study in China. Cancer Res 61:3406-3409, 2001 (Pubitemid 32695033)
30. Chang HJ, Jee CD, Kim WH: Mutation and altered expression of beta-catenin during gallbladder carcinogenesis. Am J Surg Pathol 26:758-766, 2002 (Pubitemid 34546941)
31. Kim YT, Kim J, Jang YH, et al: Genetic alterations in gallbladder adenoma, dysplasia and carcinoma. Cancer Lett 169:59-68, 2001 (Pubitemid 32532097)
32. Watanabe H, Date K, Itoi T, et al: Histological and genetic changes in malignant transformation of gallbladder adenoma. Ann Oncol 10:136-139, 1999 (suppl 4)
33. Wistuba II, Miquel JF, Gazdar AF, et al: Gallbladder adenomas have molecular abnormalities different from those present in gallbladder carcinomas. Hum Pathol 30:21-25, 1999 (Pubitemid 29037389)
34. Shimotake T, Aoi S, Tomiyama H, et al: DPC-4 (Smad-4) and K-ras gene mutations in biliary tract epithelium in children with anomalous pancreaticobiliary ductal union. J Pediatr Surg 38:694-697, 2003 (Pubitemid 36534793)
35. Tannapfel A, Sommerer F, Benicke M, et al: Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 52:706-712, 2003 (Pubitemid 36528874)
36. Rashid A, Ueki T, Gao YT, et al: K-ras mutation, p53 overexpression, and microsatellite instability in biliary tract cancers: A population-based study in China. Clin Cancer Res 8:3156-3163, 2002 (Pubitemid 35155025)
37. Suto T, Habano W, Sugai T, et al: Aberrations of the K-ras, p53, and APC genes in extrahepatic bile duct cancer. J Surg Oncol 73:158-163, 2000 (Pubitemid 30174210)
38. Tannapfel A, Benicke M, Katalinic A, et al: Frequency of p16(INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver. Gut 47:721-727, 2000
39. Ohashi K, Nakajima Y, Kanehiro H, et al: Ki-ras mutations and p53 protein expressions in intrahepatic cholangiocarcinomas: Relation to gross tumor morphology. Gastroenterology 109:1612-1617, 1995
40. Saetta AA, Papanastasiou P, Michalopoulos NV, et al: Mutational analysis of BRAF in gallbladder carcinomas in association with K-ras and p53 mutations and microsatellite instability. Virchows Arch 445:179-182, 2004 (Pubitemid 39215549)
41. Goldenberg D, Rosenbaum E, Argani P, et al: The V599E BRAF mutation is uncommon in biliary tract cancers. Mod Pathol 17:1386-1391, 2004 (Pubitemid 39472994)
42. Leone F, Cavalloni G, Pignochino Y, et al: Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma. Clin Cancer Res 12:1680-1685, 2006
43. Gwak GY, Yoon JH, Shin CM, et al: Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas. J Cancer Res Clin Oncol 131:649-652, 2005 (Pubitemid 41502207)
44. Nakazawa K, Dobashi Y, Suzuki S, et al: Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. J Pathol 206:356-365, 2005 (Pubitemid 40903200)
45. Riener MO, Bawohl M, Clavien PA, et al: Rare PIK3CA hotspot mutations in carcinomas of the biliary tract. Genes Chromosomes Cancer 47:363-367, 2008 (Pubitemid 351451790)
46. Malumbres M, Barbacid M: RAS oncogenes: The first 30 years. Nat Rev Cancer 3:459-465, 2003 (Pubitemid 37328850)
47. Levi S, Urbano-Ispizua A, Gill R, et al: Multiple K-ras codon 12 mutations in cholangiocarcinomas demonstrated with a sensitive polymerase chain reaction technique. Cancer Res 51:3497-3502, 1991
48. Kiguchi K, Carbajal S, Chan K, et al: Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma. Cancer Res 61:6971-6976, 2001 (Pubitemid 32946479)
49. Hansel DE, Rahman A, Hidalgo M, et al: Identification of novel cellular targets in biliary tract cancers using global gene expression technology. Am J Pathol 163:217-229, 2003 (Pubitemid 36759606)
50. Kornprat P, Rehak P, Ruschoff J, et al: Expression of IGF-I, IGF-II, and IGF-IR in gallbladder carcinoma: A systematic analysis including primary and corresponding metastatic tumours. J Clin Pathol 59:202-206, 2006 (Pubitemid 43235588)
51. Alvaro D, Barbaro B, Franchitto A, et al: Estrogens and insulin-like growth factor 1 modulate neoplastic cell growth in human cholangiocarcinoma. Am J Pathol 169:877-888, 2006 (Pubitemid 44411954)
52. Wolf S, Lorenz J, Mössner J, et al: Treatment of biliary tract cancer with NVP-AEW541: Mechanisms of action and resistance. World J Gastroenterol 16:156-166, 2010
53. Ueki T, Hsing AW, Gao YT, et al: Alterations of p16 and prognosis in biliary tract cancers from a population-based study in China. Clin Cancer Res 10:1717-1725, 2004 (Pubitemid 38435563)
54. Tannapfel A, Weinans L, Geissler F, et al: Mutations of p53 tumor suppressor gene, apoptosis, and proliferation in intrahepatic cholangiocellular carcinoma of the liver. Dig Dis Sci 45:317-324, 2000 (Pubitemid 30133893)
55. Hahn SA, Bartsch D, Schroers A, et al: Mutations of the DPC4/Smad4 gene in biliary tract carcinoma. Cancer Res 58:1124-1126, 1998 (Pubitemid 28183196)
56. Argani P, Shaukat A, Kaushal M, et al: Differing rates of loss of DPC4 expression and of p53 overexpression among carcinomas of the proximal and distal bile ducts. Cancer 91:1332-1341, 2001 (Pubitemid 32267045)
57. Su GH, Hruban RH, Bansal RK, et al: Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am J Pathol 154:1835-1840, 1999
58. Kim WY, Sharpless NE: The regulation of INK4/ARF in cancer and aging. Cell 127:265-275, 2006 (Pubitemid 44572384)
59. Levine AJ, Finlay CA, Hinds PW: P53 is a tumor suppressor gene. Cell 116:S67-S69, 2004
60. Massagué J: TGFbeta in cancer. Cell 134: 215-230, 2008
61. Yoshida S, Todoroki T, Ichikawa Y, et al: Mutations of p16Ink4/CDKN2 and p15Ink4B/MTS2 genes in biliary tract cancers. Cancer Res 55:2756-2760, 1995
62. Xu X, Kobayashi S, Qiao W, et al: Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. J Clin Invest 116:1843-1852, 2006
63. Farazi PA, Zeisberg M, Glickman J, et al: Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice. Cancer Res 66:6622-6627, 2006 (Pubitemid 44085618)
64. Hezel AF, Bardeesy N: LKB1; linking cell structure and tumor suppression. Oncogene 27:6908-6919, 2008
65. Ji H, Ramsey MR, Hayes DN, et al: LKB1 modulates lung cancer differentiation and metastasis. Nature 448:807-810, 2007 (Pubitemid 47266337)
66. Shiraishi K, Okita K, Harada T, et al: Comparative genomic hybridization analysis of genetic aberrations associated with development and progression of biliary tract carcinomas. Cancer 91:570-577, 2001 (Pubitemid 32105703)
67. Gorunova L, Parada LA, Limon J, et al: Non-random chromosomal aberrations and cytogenetic heterogeneity in gallbladder carcinomas. Genes Chromosomes Cancer 26:312-321, 1999 (Pubitemid 29529576)
68. Miller G, Socci ND, Dhall D, et al: Genome wide analysis and clinical correlation of chromosomal and transcriptional mutations in cancers of the biliary tract. J Exp Clin Cancer Res 28:62, 2009
69. Ooi A, Suzuki S, Nakazawa K, et al: Gene amplification of Myc and its coamplification with ERBB2 and EGFR in gallbladder adenocarcinoma. Anticancer Res 29:19-26, 2009
70. Shibata T, Kokubu A, Gotoh M, et al: Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. Gastroenterology 135:1358-1368, 2008
71. Fava G, Marzioni M, Benedetti A, et al: Molecular pathology of biliary tract cancers. Cancer Lett 250:155-167, 2007 (Pubitemid 46529440)
72. Okabe H, Beppu T, Hayashi H, et al: Hepatic stellate cells may relate to progression of intrahepatic cholangiocarcinoma. Ann Surg Oncol 16:2555-2564, 2009
73. Chuaysri C, Thuwajit P, Paupairoj A, et al: Alpha-smooth muscle actin-positive fibroblasts promote biliary cell proliferation and correlate with poor survival in cholangiocarcinoma. Oncol Rep 21:957-969, 2009
74. Kobayashi N, Hiraoka N, Yamagami W, et al: FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res 13:902-911, 2007 (Pubitemid 46340366)
75. Terada T, Matsunaga Y: Increased mast cells in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Hepatol 33:961-966, 2000
76. Zen Y, Harada K, Sasaki M, et al: Intrahepatic cholangiocarcinoma escapes from growth inhibitory effect of transforming growth factor-beta1 by over-expression of cyclin D1. Lab Invest 85:572-581, 2005 (Pubitemid 40523947)
77. Benckert C, Jonas S, Cramer T, et al: Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells. Cancer Res 63:1083-1092, 2003 (Pubitemid 36278442)
78. Sirica AE, Dumur CI, Campbell DJ, et al: Intrahepatic cholangiocarcinoma progression: Prognostic factors and basic mechanisms. Clin Gastroenterol Hepatol 7:S68-S78, 2009
79. Yoshikawa D, Ojima H, Iwasaki M, et al: Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer 98:418-425, 2008 (Pubitemid 351161240)
80. Giatromanolaki A, Sivridis E, Simopoulos C, et al: Hypoxia inducible factors 1alpha and 2alpha are associated with VEGF expression and angiogenesis in gallbladder carcinomas. J Surg Oncol 94:242-247, 2006 (Pubitemid 44289989)
81. Park BK, Paik YH, Park JY, et al: The clinicopathologic significance of the expression of vascular endothelial growth factor-C in intrahepatic cholangiocarcinoma. Am J Clin Oncol 29:138-142, 2006 (Pubitemid 44270951)
82. Hida Y, Morita T, Fujita M, et al: Vascular endothelial growth factor expression is an independent negative predictor in extrahepatic biliary tract carcinomas. Anticancer Res 19:2257-2260, 1999 (Pubitemid 29392531)
83. Elmore LW, Sirica AE: Phenotypic characterization of metaplastic intestinal glands and ductular hepatocytes in cholangiofibrotic lesions rapidly induced in the caudate liver lobe of rats treated with furan. Cancer Res 51:5752-5759, 1991
84. Elmore LW, Sirica AE: "Intestinal-type" of adenocarcinoma preferentially induced in right/caudate liver lobes of rats treated with furan. Cancer Res 53:254-259, 1993
85. Sirica AE: Biliary proliferation and adaptation in furan-induced rat liver injury and carcinogenesis. Toxicol Pathol 24:90-99, 1996
86. Radaeva S, Ferreira-Gonzalez A, Sirica AE: Overexpression of C-NEU and C-MET during rat liver cholangiocarcinogenesis: A link between biliary intestinal metaplasia and mucin-producing cholangiocarcinoma. Hepatology 29:1453-1462, 1999 (Pubitemid 29211047)
87. Lai GH, Sirica AE: Establishment of a novel rat cholangiocarcinoma cell culture model. Carcinogenesis 20:2335-2340, 1999
88. Lai GH, Zhang Z, Shen XN, et al: ErbB-2/neu transformed rat cholangiocytes recapitulate key cellular and molecular features of human bile duct cancer. Gastroenterology 129:2047-2057, 2005 (Pubitemid 41772979)
89. Sirica AE, Zhang Z, Lai GH, et al: A novel "patient-like" model of cholangiocarcinoma progression based on bile duct inoculation of tumorigenic rat cholangiocyte cell lines. Hepatology 47:1178-1190, 2008
90. Olive KP, Jacobetz MA, Davidson CJ, et al: Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324:1457-1461, 2009
91. Engelman JA, Chen L, Tan X, et al: Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14:1351-1356, 2008
92. Sharpless NE, Depinho RA: The mighty mouse: Genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 5:741-754, 2006 (Pubitemid 44323701)
93. Wu Q, Kiguchi K, Kawamoto T, et al: Therapeutic effect of rapamycin on gallbladder cancer in a transgenic mouse model. Cancer Res 67:3794-3800, 2007 (Pubitemid 46762166)
94. Kuper H, Ye W, Broomé U, et al: The risk of liver and bile duct cancer in patients with chronic viral hepatitis, alcoholism, or cirrhosis. Hepatology 34:714-718, 2001 (Pubitemid 32927995)
95. Shaib YH, El-Serag HB, Davila JA, et al: Risk factors of intrahepatic cholangiocarcinoma in the United States: A case-control study. Gastroenterology 128:620-626, 2005 (Pubitemid 40585364)
96. Alpini G, Elias I, Glaser SS, et al: Gamma-interferon inhibits secretin-induced choleresis and cholangiocyte proliferation in a murine model of cirrhosis. J Hepatol 27:371-380, 1997 (Pubitemid 27366219)
97. Valle J, Wasan H, Palmer DH, et al: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. NEJM 362:1273-1281, 2010
98. Malka D, Trarbach T, Fartoux L, et al: A multicenter, randomized phase II trial of gemcitabine and oxaliplatin (GEMOX) alone or in combination with biweekly cetuximab in the first-line treatment of advanced biliary cancer: Interim analysis of the BINGO trial. J Clin Oncol 27:XXXX, 2009 (suppl 15s; abstr 4520)
99. Philip PA, Mahoney MR, Allmer C, et al: Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol 24:3069-3074, 2006 (Pubitemid 46638942)
100. Ramanathan RK, Belani CP, Singh DA, et al: A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol 64:777-783, 2009
101. Bekaii-Saab TMP, Xiaobai L, Saji M, et al: A multi-institutional study of AZD6244 (ARRY-142886) in patients with advanced biliary cancers. 100th Annual Meeting of the American Association for Cancer Research, Denver, CO, April 18-22, 2009 (abstr LB-129)
102. Bengala C, Bertolini F, Malavasi N, et al: Sorafenib in patients with advanced biliary tract carcinoma: A phase II trial. Br J Cancer 102:68-72, 2010
103. El-Khoueiry AB, Rankin C, Lenz HJ, et al: SWOG 0514: A phase II study of sorafenib (BAY 43-9006) as single agent in patients (pts) with unresectable or metastatic gallbladder cancer or cholangiocarcinomas. J Clin Oncol 25:XXXX, 2007 (suppl 18s; abstr 4639)
104. Zhu AX, Meyerhardt JA, Blaszkowsky LS, et al: Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in patients with advanced biliary tract cancers and correlation of FDG-PET changes with clinical outcome: A phase II study. Lancet Oncol 11:48-54, 2010
105. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004 (Pubitemid 38637993)
106. Tsao MS, Sakurada A, Cutz JC, et al: Erlotinib in lung cancer: Molecular and clinical predictors of outcome. N Engl J Med 353:133-144, 2005 (Pubitemid 41058345)
107. Paule B, Herelle MO, Rage E, et al: Cetuximab plus gemcitabine- oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas. Oncology 72:105-110, 2007 (Pubitemid 350249137)
108. Sprinzl MF, Schimanski CC, Moehler M, et al: Gemcitabine in combination with EGF-receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: A case report. BMC Cancer 6:190, 2006
109. Holen KD, Mahoney MR, LoConte NX, et al: Efficacy report of a multicenter phase II trial testing a biologic-only combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer (BC): A Phase II Consortium (P2C) study. J Clin Oncol 26:XXXX, 2008 (suppl; abstr 4522)
110. Cho JY, Paik YH, Chang YS, et al: Capecitabine combined with gemcitabine (CapGem) as firstline treatment in patients with advanced/metastatic biliary tract carcinoma. Cancer 104:2753-2758, 2005 (Pubitemid 41798285)
111. Iyer RV, Gibbs J, Kuvshinoff B, et al: A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: A single-institution prospective study. Ann Surg Oncol 14:3202-3209, 2007 (Pubitemid 47594289)
112. Knox JJ, Hedley D, Oza A, et al: Combining gemcitabine and capecitabine in patients with advanced biliary cancer: A phase II trial. J Clin Oncol 23:2332-2338, 2005 (Pubitemid 46218726)
113. Riechelmann RP, Townsley CA, Chin SN, et al: Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer. Cancer 110: 1307-1312, 2007 (Pubitemid 47435603)
114. Harder J, Riecken B, Kummer O, et al: Out-patient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer. Br J Cancer 95:848-852, 2006 (Pubitemid 44498100)
115. Gebbia N, Verderame F, Di Leo, et al: A phase II study of oxaliplatin (O) and gemcitabine (G) first line chemotherapy in patients with advanced biliary tract cancers. J Clin Oncol 23:XXXX, 2005 (suppl 16S; abstr 4132)
116. André T, Tournigand C, Rosmorduc O, et al: Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: A GERCOR study. Ann Oncol 15:1339-1343, 2004 (Pubitemid 39295020)